ArticleNature communications2020
Quantitative modeling predicts mechanistic links between pre-treatment microbiome composition and metronidazole efficacy in bacterial vaginosis.
Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- A Dive into the Invisible: The Vaginal and Endometrial Microbiota in Gynecologic and Obstetric Disorders: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- Resource landscape shapes the composition and stability of the human vaginal microbiota.PLoS biology · 2026Article
- The effects of the Caribbean medicinal plant Argemone mexicana on Gardnerella vaginalis using a co-culture method with vaginal Lactobacillus spp.Scientific reports · 2026Article
- Natural Molecules, Nutraceuticals, and Engineered Nanosystems: A Comprehensive Strategy for CombatingMicroorganisms · 2025Review
- Drug and therapeutic intravaginal delivery targeting diseases in the female reproductive tract: A mathematical modeling perspective.Journal of controlled release : official journal of the Controlled Release Society · 2025Review
- Article
- Dual probiotic and antibiotic therapy targeting bacterial vaginosis: an integrated experimental/computational modeling perspective.Biomedical engineering advances · 2025Article
- In Vitro Bactericidal Activity of a Neomycin-Polymyxin B-Nystatin Combination Compared to Metronidazole and Clindamycin Against the Main Bacteria Involved in Bacterial Vaginosis and Aerobic Vaginitis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- An in silico framework for the rational design of vaginal probiotic therapy.PLoS computational biology · 2025Article
- Review
- The human vaginal microbiota: from clinical medicine to models to mechanisms.Current opinion in microbiology · 2024Review
- Uterine fibroids and longitudinal profiles of the vaginal microbiota in a cohort presenting for transvaginal ultrasound.PloS one · 2024Article
- Prevotella and Gardnerella Are Associated With Treatment Failure Following First-line Antibiotics for Bacterial Vaginosis.The Journal of infectious diseases · 2023Article
- Evaluation of vaginal microbiome equilibrium states identifies microbial parameters linked to resilience after menses and antibiotic therapy.PLoS computational biology · 2023Article
- A stochastic analysis of the interplay between antibiotic dose, mode of action, and bacterial competition in the evolution of antibiotic resistance.PLoS computational biology · 2023Article
- Article
- Treatment Success Following Standard Antibiotic Treatment for Bacterial Vaginosis Is Not Associated With Pretreatment Genital Immune or Microbial Parameters.Open forum infectious diseases · 2023Article
- Roles of the Microbiota of the Female Reproductive Tract in Gynecological and Reproductive Health.Microbiology and molecular biology reviews : MMBR · 2022Review
- Astodrimer sodium and bacterial vaginosis: a mini review.Archives of gynecology and obstetrics · 2022Review
- Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis.American journal of obstetrics and gynecology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
Bacterial vaginosis is a condition associated with adverse reproductive outcomes and characterized by a shift from a Lactobacillus-dominant vaginal microbiota to a polymicrobial microbiota, consistently colonized by strains of Gardnerella vaginalis. Metronidazole is the first-line treatment; however, treatment failure and recurrence rates remain high. To understand complex interactions between Gardnerella vaginalis and Lactobacillus involved in efficacy, here we develop an ordinary differential equation model that predicts bacterial growth as a function of metronidazole uptake, sensitivity, and metabolism. The model shows that a critical factor in efficacy is Lactobacillus sequestration of metronidazole, and efficacy decreases when the relative abundance of Lactobacillus is higher pre-treatment. We validate results in Gardnerella and Lactobacillus co-cultures, and in two clinical cohorts, finding women with recurrence have significantly higher pre-treatment levels of Lactobacillus relative to bacterial vaginosis-associated bacteria. Overall results provide mechanistic insight into how personalized differences in microbial communities influence vaginal antibiotic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.